Brain training may reshape brain chemistry in schizophrenia

NCT ID NCT07788755

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study investigates whether computerized cognitive training can change brain metabolism and excitatory/inhibitory balance in adults with schizophrenia. Participants will undergo brain imaging and EEG before and after about 10 hours of either perceptual discrimination or cognitive control training. The goal is to understand the neurobiological mechanisms behind cognitive improvements, potentially leading to better targeted therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Computerized cognitive training programs (perceptual discrimination training and cognitive control training) delivered via BrainHQ platform
What this could lead to
If successful, this could reveal how brain training changes brain chemistry and function, potentially guiding more effective cognitive therapies for schizophrenia.
What could go wrong
This is an early mechanistic study, not a treatment trial. Results may not translate to clinical benefits, and individual responses to training can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 168 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All participants (healthy control and SZ): * Age: 18-79 * Have given written informed consent * Be able to read and write in English * General health status: Participants should be in good general physical health (no major neurological disorder or head injury with prolonged unconsciousness, and no current moderate or severe substance use disorder) * Geographic location: Minnesota counties that are approximately within 1 hour driving distance to Twin Cities, including, but not limited to, Hennepin, Ramsey, Washington, Anoka, Wright, Carver, Scott, Dakota, Sherburn * Agree to refrain from using recreational drugs for 1 week prior to each scanning session, including, but not limited to, marijuana For people with schizophrenia (SZ): * Current DSM-5 diagnosis of schizophrenia or schizoaffective disorder. Participants should be in stable psychiatric health, evidenced by no suicide attempt or psychiatric hospitalization within the past 1 month. (Initial diagnosis will be assessed using SCID 5 or MINI-7, and confirmation of ongoing SZ status and symptom changes will be monitored at each major timepoint using BPRS.) * All SZ must have achieved clinical stability, defined as outpatient status for at least one month prior to study participation, plus stable doses of psychiatric medications for at least 1 month prior to study participation (as reported by participants and confirmed via medication list (procured by participants via their own medical or pharmacy records) and/or current pill bottle labels). * All participants should have symptom ratings below a rating of 7 "extremely severe" on a severity scale of 1-7 on the BPRS and/or below grade 3 on longitudinal assessment defined by (as determined by the PI): * Grade 1: Worsening of 1 point on any item within each BPRS factor * Grade 2: Worsening of 2 points on any item within each BPRS factor * Grade 3: Worsening of 3+ points on any item within each BPRS factor, or a change to a rating of extremely severe * Grade 4: Suicide attempt with intent to die Exclusion Criteria: Exclusion criteria for both groups are: * Presence of major neurological disorder * Conditions preventing MR scanning or other MRI contraindications: Implanted devices or ferromagnetic objects, current pregnancy (positive pregnancy test on day of MRI scanning or currently breast-feeding), etc. Significant movement disorders including tardive dyskinesia that could disrupt MRI and MRS recordings. Medically significant condition considered unsuitable for the current study (e.g., epilepsy, etc.) * Estimated IQ \< 70 * Other relevant comorbidity (e.g., epilepsy, developmental disability) or visual impairment * Presence of current substance use disorder (moderate or severe; excluding caffeine and nicotine), as measured by the MINI-7 or SCID 5 based on DSM-5 criteria. For healthy controls, additionally: * Personal or immediate first-degree family history of a psychotic or mood disorder. Specifically, current or past history of meeting DSM-5 criteria for schizophrenia spectrum or other psychotic disorders, or Bipolar I or II Disorder, major depressive disorder, posttraumatic stress disorder, panic disorder, obsessive compulsive disorder, dysthymic disorder. Those with a first or second-degree relative with a current or past history of meeting DSM-5 criteria for schizophrenia or other psychotic disorders or bipolar I or II disorder, because they might have an underlying genetic susceptibility for psychosis symptoms. * Presence of symptoms of the following DSM-5 disorders (as assessed by the MINI-7 or SCID 5): * Major Depressive Episode * Suicidality * Manic and Hypomanic Episodes * Panic disorder * Obsessive-Compulsive Disorder * Posttraumatic Stress Disorder * Alcohol Use Disorder * Substance Use Disorder (Non-Alcoholic) * Psychotic Disorders and Mood Disorders with Psychotic Features * Medication or substance induced psychosis * Major Depressive Disorder (MDD) * MDD with Psychotic Features * Bipolar I * Bipolar II * Other Specified Bipolar and Related Disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Psychotic Disorders schizoaffective disorder schizophrenia vision disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Magnetic Resonance Research, University of Minnesota

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.